To the full analysis
Inhibrx Biosciences stock: growth
INBXInhibrx Biosciences reported $1.3M in revenue for fiscal 2025, up 550% on the prior year, down 36.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−16.6%
per year from 2016 to 2025, per share −8.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | −36.7% | −16.6% |
| Revenue per share | −30.2% | −8.3% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $6.67M | −$8.27M | −$18.32M |
| 2017 | $8.39M | −$19.44M | −$20.09M |
| 2018 | $8.6M | −$31.16M | −$24.52M |
| 2019 | $9.09M | −$51.4M | −$33.89M |
| 2020 | $12.81M | −$76.12M | −$49.33M |
| 2021 | $7.13M | −$81.77M | −$81.19M |
| 2022 | $2.19M | −$145.23M | −$115.99M |
| 2023 | $1.8M | −$241.36M | −$197.9M |
| 2024 | $200K | $1.69B | −$197.01M |
| 2025 | $1.3M | −$140.06M | −$129.83M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Aug 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.